Our mobile IV therapy service will improve how you feel with IV hydration in the comfort and privacy of your home, hotel, or office
For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions
Asian J Psych
Otros beneficios potenciales incluyen mejora de la funcin heptica en pacientes con enfermedad del hgado graso no alcohlico, aunque esta indicacin an est siendo investigada y no cuenta con aprobacin de la FDA